Developing next-generation targeted cancer immunotherapy treatments
iOmx Therapeutics focuses on the development of next-generation, first-in-class cancer immune-checkpoint inhibitors. By systematically screening human tumor cells, the Company has identified a number of novel targets and is building a clinical pipeline of drug candidates to treat a range of target-related indications.
The Company was founded on the successful concept of cancer immune-checkpoint therapy, which works by breaking down the inherent resistance mechanisms of tumors against immune attack. Reactivating the host immune response by neutralizing these negative interactions is the key idea behind cancer immune-checkpoint therapy.